###begin article-title 0
Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
The p53 protein is activated by genotoxic stress, oncogene expression and during senescence, p53 transcriptionally activates genes involved in growth arrest and apoptosis. p53 activation is regulated by post-translational modification, including phosphorylation of the N-terminal transactivation domain. Here, we have examined how Glycogen Synthase Kinase (GSK3), a protein kinase involved in tumorigenesis, differentiation and apoptosis, phosphorylates and regulates p53.
###end p 2
###begin title 3
Results
###end title 3
###begin p 4
###xml 395 404 385 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro.</italic>
###xml 529 537 512 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo.</italic>
###xml 724 732 701 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo.</italic>
The 2 isoforms of GSK3, GSK3alpha and GSK3beta, phosphorylate the sequence Ser-X-X-X-Ser(P) when the C-terminal serine residue is already phosphorylated. Several p53 kinases were examined for their ability to create GSK3 phosphorylation sites on the p53 protein. Our results demonstrate that phosphorylation of serine 37 of p53 by DNA-PK creates a site for GSK3beta phosphorylation at serine 33 in vitro. GSK3alpha did not phosphorylate p53 under any condition. GSK3beta increased the transcriptional activity of the p53 protein in vivo. Mutation of either serine 33 or serine 37 of p53 to alanine blocked the ability of GSK3beta to regulate p53 transcriptional activity. GSK3beta is therefore able to regulate p53 function in vivo. p53's transcriptional activity is commonly increased by DNA damage. However, GSK3beta kinase activity was inhibited in response to DNA damage, suggesting that GSK3beta regulation of p53 is not involved in the p53-DNA damage response.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
GSK3beta can regulate p53's transcriptional activity by phosphorylating serine 33. However, GSK3beta does not appear to be part of the p53-DNA damage response pathway. Instead, GSK3beta may provide the link between p53 and non-DNA damage mechanisms for p53 activation.
###end p 6
###begin title 7
Background
###end title 7
###begin p 8
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 408 409 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 569 570 569 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 571 572 571 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 573 574 573 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
The p53 tumor suppressor gene is activated during several cellular processes. These include DNA damage caused by Ionizing Radiation and genotoxic agents [1], by expression of activated oncogenes such as ras or myc [2], or during progression of primary cells to senescence [3]. The activation of p53 by these diverse stimuli can initiate either growth arrest or apoptosis depending on the cellular context [1,2,3]. p53 posses sequence-specific DNA binding activity and functions in the cell as a transcriptional regulator. Many p53 regulated genes have been identified [3,4,5], and the majority of the cellular effects of p53 activation can be attributed to the activation of these p53 target genes.
###end p 8
###begin p 9
###xml 283 284 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 562 565 562 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arf</sup>
###xml 572 573 572 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 579 582 579 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Arf</sup>
###xml 667 668 667 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 835 836 835 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 927 929 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 930 932 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 994 996 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1064 1066 1064 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1067 1069 1067 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1264 1266 1264 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1267 1269 1267 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1270 1272 1270 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1273 1275 1273 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1391 1393 1391 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
The mechanism of p53 activation in response to either DNA damage or oncogene expression occurs through stabilization of the p53 protein. In unstimulated cells, the mdm2 protein binds to the N-terminal transactivation domain of p53 and targets it for ubiquitin-dependent degradation [6,7]. Activation of p53 requires disruption of the mdm2-p53 interaction to allow p53 accumulation in the cell. 2 distinct mechanisms for p53 activation have so far been elucidated. The expression of oncogenes such as ras in untransformed cells stimulates transcription of the p14Arf gene [2]. p14Arf binds to and sequesters mdm2, allowing free p53 protein to accumulate in the cells [8]. Activation of p53 by DNA damage is also brought about by inhibition of p53-mdm2 interaction. The product of the Ataxia Telangiectasia gene, the ATM protein kinase [9], directly phosphorylates serine 15 of the p53 protein in response to Ionizing Radiation [10,11]. In addition, ATM phosphorylates and activates chk2 kinase [12]. Activated chk2 can then directly phosphorylate serine 20 of p53 [13,14]. ATM therefore controls the phosphorylation of serines 15 and 20 of p53. In addition, DNA damage increases the phosphorylation of serines 33 and 37 of p53 through an ATM-independent mechanism [15,16,17,18]. These DNA damage-induced phosphorylations of p53 block the binding of mdm2 to the N-terminal of the p53 protein [18]. Thus phosphorylation of the p53 protein in response to DNA damage or expression of p14Arf prevents mdm2 binding and p53 protein then accumulates in the cell.
###end p 9
###begin p 10
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 705 707 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 711 713 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 721 723 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 724 726 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 841 843 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 844 846 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 847 849 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 850 852 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 935 942 935 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Although stabilization of the p53 protein is the initial step in p53 activation, subsequent steps, including activation of p53's DNA binding activity and changes in p53's transcriptional activity, are also involved. For example, p53's DNA binding activity is increased by the DNA damage-induced acetylation of the C-terminal of p53 [16,19], and this acetylation requires the prior phosphorylation of the N-terminal of p53 [16]. In addition, phosphorylation of the N-terminal transactivation domain of p53 may be required to stimulate transcriptional activation of p53 target genes. Multiple phosphorylation sites have been detected in the N-terminal of p53, including serines 6, 9, 15, 20, 33, 37 and 46 [10,11,12,13,14, 20,21,22]. While phosphorylation of serines 15 and 20 of p53 are clearly dependent on the ATM and chk2 protein kinases [10,11,12,13,14], the kinases responsible for phosphorylation of the remaining serine residues in vivo is not clear.
###end p 10
###begin p 11
###xml 313 315 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 316 318 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 402 404 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 405 407 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 408 410 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 411 413 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 526 528 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 529 531 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
The activation of p53 by DNA damage or oncogenes such as ras results in either growth arrest or apoptosis of the affected cell. In this study, we have examined how Glycogen Synthase Kinase 3beta (GSK3beta), a protein kinase involved in tumorigenesis, differentiation and apoptosis, regulates the function of p53 [23,24]. GSK3beta phosphorylates several transcription factors, including NFATc and HSF1 [24,25,26,27]. GSK3beta is constitutively active in resting cells but is inhibited when cells are exposed to growth factors [24,28].
###end p 11
###begin p 12
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 203 205 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 338 340 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 341 343 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 344 346 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 404 405 401 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 406 407 403 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 408 409 405 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
GSK3 inhibition occurs when the p110-PI 3-kinase/Protein Kinase B (PKB) pathway is activated by growth factors [23,24,25,29]. Activated PKB then phosphorylates GSK3beta, inhibiting GSK3 kinase activity [29]. This activation of the p110-PI 3-kinase/PKB pathway, and inhibition of GSK3, delivers a strong anti-apoptotic signal to the cell [23,24,25]. Given the well characterized role of p53 in apoptosis [3,4,5], we examined if GSK3p participates in the regulation of the p53 protein.
###end p 12
###begin p 13
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 470 478 463 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 583 591 573 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo,</italic>
GSK3 phosphorylates the consensus sequence Ser-X-X-X-Ser(P), where the C-terminal serine residue is already phosphorylated [24,28]. Thus GSK3 only phosphorylates target proteins which have already been phosphorylated by a separate, priming kinase. p53 contains 5 potential GSK3 phosphorylation sites, 3 in the N-terminal transactivation domain and 2 in the C-terminal regulatory domain. Here, we show that GSK3beta, but not GSK3alpha, can phosphorylate serine 33 of p53 in vitro when serine 37 is already phosphorylated. Further, GSK3beta can increase p53's transcriptional activity in vivo, and this activation is lost when serine 33 is mutated to alanine.
###end p 13
###begin title 14
Results
###end title 14
###begin p 15
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 901 903 887 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
The p53 protein contains several serine residues which are located within potential GSK3 phosphorylation sites. Protein kinases which can phosphorylate p53 within these predicted GSK3 sites include MAP kinase, Protein Kinase A, Protein Kinase C, Casein Kinase II, Jun kinase (JNK) and DNA-dependent Protein Kinase (DNA-PK) [30,31,32,33,34,35]. These kinases were examined to determine if they can act as the priming kinase for either of the 2 isoforms of GSK3, GSK3alpha and GSK3beta. The general protocol was to incubate purified priming kinases with p53-GST fusion protein and ATP for 5 h, then heat inactivate the priming kinase. Preliminary experiments indicated that each of the tested kinases was able to phosphorylate p53-GST under the experimental conditions (data not shown). Aliquots of the prephosphorylated p53-GST were then incubated with or without recombinant GSK3alpha or GSK3beta and 32P-ATP to measure p53 phosphorylation.
###end p 15
###begin p 16
###xml 149 150 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 228 229 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 312 321 291 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro.</italic>
###xml 436 437 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 598 600 577 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 738 739 710 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 977 978 939 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1168 1169 1119 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1226 1235 1177 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro,</italic>
p53-GST preincubated in buffer alone, and then exposed to the heat inactivation protocol was not phosphorylated by either GSK3alpha or GSK3beta (fig 1, Control). Autophosphorylation of GSK3alpha and GSK3beta can be seen (figure 1). Unphosphorylated p53-GST is therefore not a substrate for GSK3alpha or GSK3beta in vitro. p53-GST was then prephosphorylated with MAP kinase, S6 kinase, Protein Kinase A, DNA-PK and Protein Kinase C (fig 1) or Casein Kinase II and JNK1/JNK2 (data not shown). Following incubation in each of the primary kinases, the prephosphorylated p53-GST was then incubated with 32P-ATP and either GSK3alpha or GSK3beta. Prephosphorylation of p53-GST by MAP kinase, S6 kinase, Protein Kinase A or Protein Kinase C (fig 1) or Casein Kinase II or JNK1 or JNK 2 (data not shown) failed to create a phosphorylation site for either GSK3alpha or GSK3beta. However, prephosphorylation of p53-GST by DNA-PK resulted in strong phosphorylation of p53 by GSK3beta (fig 1) but not GSK3alpha. GST protein alone incubated with DNA-PK was not phosphorylated by GSK3beta (data not shown). Since there was no significant phosphorylation of p53-GST by GSK3alpha (fig 1), this indicates that phosphorylation of p53 by DNA-PK, in vitro, creates a site for GSK3beta to phosphorylate p53.
###end p 16
###begin p 17
###xml 0 35 0 32 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Phosphorylation of p53 by GSK3&#946;.</bold>
###xml 379 381 354 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
Phosphorylation of p53 by GSK3beta. p53-GST (2 mug) was incubated in the absence (Control) or presence of the indicated protein kinase as described in methods. Primary kinases were then heat inactivated (65degreesC/15 min). Aliquots of the phosphorylated p53-GST were then incubated in the absence (-), or presence of recombinant GSK3alpha (alpha) or GSK3beta (beta) and 10 muCi 32P-ATP. Phosphorylated p53-GST (0.25 mug total p53-GST was detected by SDS-PAGE followed by auto-radiography. MAPK, MAP kinase; S6 Kin, S6 Kinase; PKA, Protein Kinase A; PKC, Protein Kinase C.
###end p 17
###begin p 18
###xml 169 171 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 290 291 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
Next, we set out to identify the exact amino-acid(s) within the p53 protein which were phosphorylated by GSK3beta. p53 is phosphorylated by DNA-PK at serines 15 and 37 [32]. Of these 2 sites, the sequence around serine 37 contains a predicted GSK3 phosphorylation site at serine 33 (figure 2, underlined). Serine 33 and 37 of p53 were individually mutated to alanine, and p53-GST fusion proteins containing these mutations prepared. The ability of DNA-PK to create a GSK3beta phosphorylation site on these p53 proteins was then examined.
###end p 18
###begin p 19
###xml 0 41 0 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink">GSK3&#946; phosphorvlates serine 33 of p53.</bold>
GSK3beta phosphorvlates serine 33 of p53. wtp53-GST (W), p53-GSTS33A (33) or p53-GSTS37A (37) were preincubated in buffer (-) or DNA-PK (+) for 5 h in the presence of excess ATP. Following heat inactivation of the DNA-PK, aliquots of the phosphorylated p53-GST fusion proteins were incubated for 30 min without (-) or with (+) GSK-3beta. Position of p53-GST and GSK3beta is indicated. The sequence of p53 around serines 15 and 37 is shown below the figure.
###end p 19
###begin p 20
###xml 72 73 69 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 188 189 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 358 359 346 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
In the absence of p53, no phosphorylation by GSK3beta was detected (fig 2). Unphosphorylated p53-GST was not a substrate for GSK3beta, whereas p53-GST prephosphorylated by DNA-PK was (fig 2). Mutation of serine 33 of p53 to alanine (S33A) blocked the ability of GSK3beta to phosphorylate p53, indicating that serine 33 is the likely target for GSK3beta (fig 2, 33). Similarly, mutation of serine 37, which abolishes the DNA-PK phosphorylation site, blocks phosphorylation of p53 by GSK3beta. This indicates that p53 must be phosphorylated on serine 37 by DNA-PK before it can be phosphorylated at serine 33 by GSK3beta.
###end p 20
###begin p 21
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 41 49 41 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 779 781 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 791 793 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 201 206 <span type="species:ncbi:9606">human</span>
To examine the in vivo function of these in vitro phosphorylations, wtp53 and p53 with the S33A and S37A mutations were sub-cloned into the expression vector pcDNA3.1. These were then expressed in the human osteosarcoma cell line SAOS-2, which does not express endogenous p53 protein [33]. First, we analyzed the level of expression of each of the p53 proteins following transient expression in SAOS-2 cells. In fig 3A, approx equal amounts of wtp53, p53S33A and p53S37A were detected by western blot, indicating that they were expressed at similar levels. In fig 3B, we examined the transcriptional activity of these p53 constructs. A p53-reporter construct, p50-2, which specifically responds to wtp53 by increasing transcription of the luciferase gene, was used [described in 33]. In fig 3B, SAOS-2 cells transiently expressing vector (Con), showed minimal activation of the p53-reporter construct. Cells expressing wtp53 showed significant activation, as did cells expressing both the S33A and S37A mutations. Both the S33A and S37A mutations displayed slightly higher basal levels of transcriptional activity than the wtp53 protein.
###end p 21
###begin p 22
###xml 0 48 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink">GSK3&#946; regulates p53 transcriptional activity.</bold>
###xml 48 51 45 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A)</bold>
###xml 238 244 235 241 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B+C).</bold>
GSK3beta regulates p53 transcriptional activity.(A) SAOS-2 cells were transiently transfected with vector (pcDNA3.1), or expression vectors for wtp53, wtp53S33A (S33A) or wtp53S37A (S37A). p53 expression was detected by western blotting. (B+C). SAOS-2 cells were transiently transfected with p50-2, a p53-responsive luciferase reporter construct, and 50 ng of vector (Con), wtp53, wtp53S33A (S33A), or wtp53S37A (S37A) as indicated, beta-galactosidase activity from pCMV-Gal was used to adjust for transfection efficiency. In (B), the actual transcriptional activity of each p53 construct is shown. In (C), cells were cotransfected with an expression vector for GSK3beta (pcDGSKSbeta ; 800 ng). The transcriptional activity was calculated by dividing p53 activity in the presence of GSK3b by p53 activity in the absence of GSK3b and expressing the answer as a percentage. 0% = no increase
###end p 22
###begin p 23
###xml 172 180 169 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo,</italic>
###xml 639 641 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 1287 1288 1254 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1293 1294 1260 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1646 1648 1604 1606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1649 1651 1607 1609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1652 1654 1610 1612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1963 1964 1912 1913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 2165 2166 2105 2106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 2309 2310 2246 2247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 2622 2623 2550 2551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
Serines 33 and 37 are located within the N-terminal transcriptional activation domain of the p53 protein. To determine if GSK3beta regulates p53's transcriptional activity in vivo, a wild type GSK3beta expression vector was cotransfected with either wtp53 or p53 with mutations in serines 33 or 37. The ability of GSK3beta to activate each construct was calculated by expressing the p53 transcriptional activity in the presence of GSK3beta as a percentage of that observed in the absence of GSK3beta. On this scale, no activation by GSK3beta yields a zero percent increase in p53 transcriptional relative to p53 alone. GSK3beta alone (fig 3C, Con) did not significantly increase the activity of the luciferase reporter construct. When GSK3beta was cotransfected with wtp53, p53-dependent activity from the luciferase reporter construct was increased by 160% compared to wtp53 alone. To determine if this activation of p53 transcriptional activity required the GSK3beta phosphorylation site at serine 33, wtp53 with serine to alanine mutations at either positions 33 or 37 were cotransfected with GSK3beta. Mutation of either serine 33 or 37 significantly reduced the ability of GSK3beta to upregulate p53 transcriptional activity. This is consistent with the phosphorylation data in fig 1 and 2, which indicated that serine 37 phosphorylation is required for the subsequent phosphorylation of serine 33 by GSK3beta. These results suggests that GSK3beta may be a physiological regulator of the p53 protein. GSK3beta is constitutively active in resting cells, and is inactivated by PKB through the growth factor dependent p110-PI 3-kinase pathway [25,28,29]. Thus the activity of GSK3beta in growing cells is less than that in cells arrested in Go. p53 can be activated by several distinct pathways, including DNA damage. If GSK3beta is involved in the activation of p53 by DNA damage, then GSK3beta is predicted to be upregulated in response to DNA damage. In fig 4, GSK3beta kinase activity was monitored by immunoprecipitating GSK3beta and then measuring the ability of the immunoprecipitated protein to phosphorylate a specific GSK3beta peptide substrate. In fig 4, the omission of either the peptide or the GSK3beta antibody from the assay resulted in minimal phosphorylation of the substrate peptide (fig 4). When both GSK3beta antibody and substrate peptide were employed, high levels of GSK3beta-dependent kinase activity were detected. When cells were incubated for 24 h in low serum (0.5%) to induce growth arrest in Go, the levels of GSK3beta activity were increased compared to asynchronously growing cells (fig 4, Go). When asynchronously growing cells were exposed to 5Gy or 10Gy of Ionizing Radiation to cause DNA damage, the levels of GSK3beta activity were reduced. Similar results were seen using p53-GST as the substrate for GSK3beta phosphorylation in the kinase assay (data not shown). This implies that the phosphorylation of serine 33 of p53 by GSK3beta would be decreased in cells exposed to DNA damage, but elevated in cells growth arrested in Go.
###end p 23
###begin p 24
###xml 0 53 0 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Ionizing Radiation inhibits GSK3&#946; kinase activity.</bold>
###xml 226 230 223 227 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Pep:</bold>
###xml 354 359 351 356 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Cell:</bold>
###xml 471 474 468 471 <bold xmlns:xlink="http://www.w3.org/1999/xlink">IR:</bold>
Ionizing Radiation inhibits GSK3beta kinase activity. SAOS-2 cells were immunoprecipitated with anti-GSK3 antibody and incubated with CREB phosphopeptide substrate. Total CPM incorporated into the substrate peptide are shown. Pep: Assays carried out with or without peptide. Ab: Immunoprecipitation carried out with either IgG or anti-GSK3 antibody (+). Cell: Cells were either growing asynchronously (+) or preincubated for 24 h in 0.5% Serum to induce quiescence (Go). IR: Cells were exposed to 5 or 10Gy of Ionizing Radiation and allowed to recover for 60 min.
###end p 24
###begin title 25
Discussion
###end title 25
###begin p 26
###xml 62 70 62 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 342 344 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 405 413 384 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo,</italic>
###xml 475 477 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 478 480 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 481 483 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 484 486 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 593 595 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 524 528 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Several p53 kinases were examined for their ability to create in vitro GSK3 phosphorylation sites on p53. Phosphorylation of p53 by DNA-PK created a phosphorylation site for GSK3beta, but not for GSK3alpha. GSK3alpha and GSK3beta have 98% homology within the kinase domain, although regions N- and C-terminal to this are less well conserved [36]. GSK3alpha and GSK3beta have similar substrate specificity in vivo, and are regulated in parallel in response to growth factors [24,27,28,29]. However, disruption of GSK3beta in mice results in embryonic lethality and impaired NFkappa B function [37], indicating that GSK3alpha cannot substitute for GSK3beta in this model system. GSK3alpha and GSK3beta therefore have overlapping cellular functions, but each isoform also regulates distinct signaling pathways. Our results clearly show that p53 phsophorylation is specific for GSK3beta.
###end p 26
###begin p 27
###xml 222 229 216 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 494 496 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 497 499 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 500 502 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 503 505 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 506 508 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 509 511 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 591 593 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
The GSK3beta phosphorylation site was identified by mutagenesis as serine 33 of p53, and we were able to show that this was dependent on prior phosphorylation of serine 37 by DNA-PK. We also examined if GSK3beta regulates in vivo p53 function through a mechanism involving serines 33 and 37 of p53. Previous studies have shown that phosphorylation of serines 15, 20, 33 and 37 of p53 block the interaction of p53 with mdm2, leading to stabilization and accumulation of p53 protein in the cell [10,11,13,14,15,18]. mdm2 binding is dependent on the phosphorylation status of serine 20 of p53 [15], although phosphorylation of serines 15, 33 and 37 also play a role. We did not detect any significant difference in the level of expression of p53 with single mutations in either serines 33 or 37 when compared to wtp53, indicating that single point mutations in serines 33 or 37 do not greatly alter p53 stability.
###end p 27
###begin p 28
###xml 109 110 109 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 541 549 538 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo.</italic>
###xml 663 665 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1038 1046 1020 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo.</italic>
###xml 1174 1176 1146 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1227 1229 1199 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
A key function of p53 is the transcriptional activation of genes which regulate growth arrest and apoptosis [1,2,3,4]. Individual mutation of either serine 33 or 37 slightly increased the basal transcriptional activity of the p53 protein. This is in keeping with observations made by other groups, who demonstrated that single or multiple mutations in p53 phosphorylation sites has minimal effect on the basal transcriptional activity of the p53 protein [38,39,40]. We also determined if GSK3beta could regulate p53 transcriptional activity in vivo. GSK3beta is constitutively active in resting cells, but exhibits lower activity in asynchronously growing cells [24]. To increase the activity of GSK3beta, we co-transfected GSK3beta with either wtp53 or p53 bearing serine to alanine mutations at positions 33 or 37. GSK3beta increased the transcriptional activity of wtp53, but not of p53 with mutations in either serine 33 or 37. Therefore both serine 33 and serine 37 are required for GSK3beta to activate p53 transcriptional activity in vivo. GSK3beta regulates many stress activated transcription factors. For example, GSK3beta is required for activation of NFkappa B [37], but inhibits activation of Heat Shock Factor-1 [27]. Our results indicate that GSK3beta may also be involved in the activation of the p53 protein as well.
###end p 28
###begin p 29
###xml 86 94 86 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo.</italic>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 306 314 306 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1005 1013 1002 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo.</italic>
###xml 1035 1043 1032 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo,</italic>
###xml 1201 1209 1195 1203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo.</italic>
A key question is whether DNA-PK or some other kinase phosphorylates serine 37 of p53 in vivo. DNA-PK is 460 kd DNA-activated protein kinase which participates in the cellular response to DNA damage [41]. DNA-PK is involved in DNA strand-break repair, and can phosphorylate serines 15 and serine 37 of p53 in vitro [32]. Some reports indicate that DNA-PK is required for the activation of p53 [42], but recent genetic studies have shown clearly that DNA-PK is not required for p53 activation by Ionizing Radiation [43]. Whether DNA-PK is required for p53 activation in response to other stimuli is not known. A more likely candidate is the Atr protein kinase, a kinase related to DNA-PK [44], which can regulate the phosphorylation of serine 37 of p53 in response to DNA damage. The present data indicates that transcriptional activation of p53 by GSK3beta requires both serines 33 and 37, but it does not allow us to determine if phosphorylation of serine 33 is dependent on phosphorylation of serine 37 in vivo. It is possible that, in vivo, GSK3beta directly phosphorylates serine 33 independently of serine 37, but that both residues must be phosphorylated for transcriptional activation to occur in vivo. Future studies will address this issue.
###end p 29
###begin p 30
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 87 88 87 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 89 90 89 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 502 504 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 520 522 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 585 587 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 975 977 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 978 980 963 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 981 983 966 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1097 1099 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1135 1137 1120 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1138 1140 1123 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1219 1221 1204 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1256 1258 1238 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1331 1333 1307 1309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
p53 is activated by multiple pathways, including DNA damage and oncogene activation [1,2,3]. If GSK3beta is required for the activation of p53 by DNA damage, GSK3beta activity should be regulated by DNA damage. However, when cells were exposed to Ionizing Radiation, GSK3beta kinase activity was inhibited rather than enhanced, implying decreased GSK3beta-dependent phosphorylation of p53 after DNA damage. Serine 33 of p53 is also phosphorylated by other kinases, including the CDK7-cyclin H complex [45] and p38 MAPK [46]. p38 MAPK is involved in p53 activation by genotoxic stress [46], and may be responsible for p53 phosphorylation at serine 33 in response to DNA damage. GSK3beta-dependent phosphorylation of p53 at serine 33 may be part of other p53-regulatory pathways, such as oncogene activation or apoptosis, which are not directly activated by DNA-damage. For example, activation of the p110-PI 3-kinase/PKB pathway delivers an anti-apoptotic signal to the cell [23,25,47]. Further, activation of the p110-PI 3-kinase/PKB is associated with inhibition of both p53 dependent apoptosis [48] and p53 transcriptional activity [49,50]. Although PKB has many down stream targets which may regulate these effects [47] a key target of PKB is GSK3beta [29]. Phosphorylation of GSK3beta by PKB inhibits GSK3beta kinase activity [29]. This would be predicted to block phosphorylation of serine 33 of p53 by GSK3beta, decreasing p53 transcriptional activity and therefore reducing the transcription of p53-regulated growth and pro-apoptotic proteins. However, clarification of the potential role of GSK3beta in regulating p53 activation by non-DNA damage pathways will require additional study.
###end p 30
###begin title 31
Conclusions
###end title 31
###begin p 32
###xml 204 212 194 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo,</italic>
###xml 329 337 316 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo.</italic>
This study demonstrates that GSK3beta, but not GSK3alpha, can directly phosphorylate serine 33 of p53 when serine 37 of p53 is already phosphorylated. GSK3beta can increase p53's transcriptional activity in vivo, and this activation requires serines 33 and 37 of the p53 protein. Thus GSK3beta may phosphorylate and activate p53 in vivo. However, GSK3beta is not part of the p53-DNA damage response pathway. Instead, GSK3beta may provide the link between p53 and non-DNA damage mechanisms for p53 activation, such as oncogene activation.
###end p 32
###begin title 33
Materials and methods
###end title 33
###begin title 34
Phosphorylation Reactions
###end title 34
###begin p 35
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 689 690 681 682 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 764 765 755 756 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 843 844 833 834 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 879 880 868 869 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 967 968 955 956 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 992 993 980 981 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1233 1234 1207 1208 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Wild type p53 or p53 bearing mutations in serines 33 or 37 were subcloned into pGEX-2T GST fusion vector (Pharmacia, NJ) and p53-GST purified as previously described [33]. p53-GST protein (2 mug; measured using Bio-Rad Protein assay Kit, Biorad, CA) was incubated with MAP kinase (Erk2, 10 Units, New England Biolabs, MA), Protein Kinase A (Catalytic sub-unit, 5 Units, Calbiochem, CA), S6 kinase (0.2 Units, Upstate Biotechnology, NY), Protein Kinase C (O.1 mUnits, Roche Molecular Biochemicals, IN) or DNA-PK (20 Units, Promega Corp, Wl) for 5 h at 30degreesC in the following buffers (40 mul final volume). MAP kinase and Protein Kinase A: 20 mM Hepes pH 7.2/10 mM Na-Acetate/30 mM MgCl2/0.2 mM EDTA/1 mM EDTA/I0 muM ATP. S6 Kinase: 20 mM MOPS pH 7.2/30 mM MgCl2/5 mM EGTA/1 mM DTT/I0 muM ATP. DNA-PK:25 mM Hepes pH7.5/150 mM KCI/10 mM MgCl2/20% Glycerol/0.1% NP40/20 muM ZnCl2/1 mM DTT/250 ng DNA/4.2 mM spermidine/ 10 muM ATP. PKC: 20 mM Hepes pH 7.4/ 20 mM MgCl2/ 0.2 mM EGTA/ 1 mM CaCl2/1.5 mug phosphatidylserine. Samples were then incubated at 65degreesC for 20 min to inactivate kinases, and 25% of the reaction incubated for 30 min with GSK3alpha or GSK3beta in GSK3 kinase buffer (KGB Buffer: 8 mM MOPS, pH7.2/ 10 mM MgCl2/ 0.2 mM EDTA/ 5 muM ATP/10 muCi 32P-ATP) in a final volume of 40 mul. Reactions were terminated by the addition of SDS sample buffer and p53-GST phosphorylation detected by SDS-PAGE and auotradiography. Equal amounts of p53-GST (0.25 mug) were analyzed by SDS-PAGE and equal loading confirmed by coomassie blue staining of the SDS-PAG.
###end p 35
###begin title 36
GSK3 immunokinase assay
###end title 36
###begin p 37
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 166 167 165 166 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 169 170 168 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 463 465 459 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
SAOS-2 cells (5 x 106) were lyzed in 0.5 ml of GLB buffer (50 mM Tris pH7.5/1 mM EDTA/1 mM EGTA/0.5% NP40/0.5 M NaCI/1 mM DTT/1 mM PMSF/leupeptin/aprotinin/600 muM Na3VO4/50 mM NaF). Extracts were cleared by centrifugation and incubated with GSK3 antibody (1 mug; Upstate Biotech, NY) prebound to Sepharose A/G agarose beads for 2 h. The beads were washed in 4 x 1 ml of GLB buffer and then in 2 x 1 ml of KGB buffer. Kinase reactions contained 5 muM ATP/15 muCi 32P-ATP/0.5 mug PhosphoCREB peptide in 30 mul of KGB. After incubate for 10 min at room temperature, the beads were collected by centrifugation and 20 mul of the reaction mix spotted onto circles of P81 paper (Whatman, USA). The P81 paper was washed in 4 x 10 ml changes of 100 mM phosphoric acid, dried and counted. PhosphoCREB peptide (sequence KRREILSRRPS(P)YR) was obtained from New England Biolabs, MA.
###end p 37
###begin p 38
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mutagenesis</bold>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 121 126 <span type="species:ncbi:9606">Human</span>
Mutagenesis was carried out using the Altered Sites Mutagenesis System (Promega, Wl) as previously described by us [33]. Human wild type p53 or p53 bearing mutations in serines 33 or 37 were inserted into the BamH1 site of the pcDNA3.1 expression vector (Invitrogen, CA).
###end p 38
###begin p 39
###xml 0 26 0 26 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Luciferase reporter assays</bold>
Luciferase reporter assays were carried out in the p53 null cell line SAOS-2 using the p53 specific luciferase reporter construct p50-Luc, and pCMV-beta-galatosidase to control for transfection efficiency. Cells were transfected using Lipofectin (Gibco-BRL) containing p50-Luc (1 mug), pCMV-Gal (1 mug) and pcDNAp53 (50 ng) in a final volume of 400 mul as described in the manufacturers protocol.
###end p 39
###begin title 40
Acknowledgements
###end title 40
###begin p 41
We thank J. Woodgett for GSK3beta cDNA. This work was supported by grant number CA64585 to BDP and funds from the AJCRT foundation.
###end p 41
###begin article-title 42
The role of ATM in DNA damage responses to cancer
###end article-title 42
###begin article-title 43
Activation of p53 by Oncogenes
###end article-title 43
###begin article-title 44
Genes involved in senescence and immortalization
###end article-title 44
###begin article-title 45
p53:death star
###end article-title 45
###begin article-title 46
Surfing the p53 network
###end article-title 46
###begin article-title 47
Mdm2 promotes the rapid degradation of p53
###end article-title 47
###begin article-title 48
Regulation of p53 stability by mdm2
###end article-title 48
###begin article-title 49
The lnk4a tumor suppressor gene product p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
###end article-title 49
###begin article-title 50
Ataxia Telangiectasia, cancer and the pathobiology of the ATM gene
###end article-title 50
###begin article-title 51
Enhanced phosphorylation of p53 byATM in response to DNA damage
###end article-title 51
###begin article-title 52
Activation of the ATM kinase by ionizing radiation and phosphorylation of p53
###end article-title 52
###begin article-title 53
Linkage of ATM to cell cycle regulation by the chk2 protein kinase
###end article-title 53
###begin article-title 54
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human homologs of checkpoint kinases Chk1 and Cds1 (chk2) phosphorylate p53 at multiple DNA damage-inducible sites
###end article-title 54
###begin article-title 55
Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53
###end article-title 55
###begin article-title 56
DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization
###end article-title 56
###begin article-title 57
DNA damage activates p53 through a phosphorylation-acetylation cascade
###end article-title 57
###begin article-title 58
DNA damage induces phosphorylation of the amino-terminus of p53
###end article-title 58
###begin article-title 59
DNA-damage induced phosphorylation of p53 alleviates inhibition by mdm2
###end article-title 59
###begin article-title 60
Activation of p53-sequence-specific DNA binding by acetylation of the p53 C-terminal domain
###end article-title 60
###begin article-title 61
How phosphorylation regulates the activity of p53
###end article-title 61
###begin article-title 62
p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53
###end article-title 62
###begin article-title 63
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human p53 is phosphorylated on serines 6 and 9 in response to DNA damage-inducing agents
###end article-title 63
###begin article-title 64
PI3K: Downstream Aktion blocks apoptosis
###end article-title 64
###begin article-title 65
GSK3, a master switch regulating cell-fate specification and tumorigenesis
###end article-title 65
###begin article-title 66
The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal
###end article-title 66
###begin article-title 67
Glycogen Synthase kinase-3 inhibits the DNA binding activity of NFATc
###end article-title 67
###begin article-title 68
Glycogen Synthase Kinase 3beta negatively regulates both DNA-Binding and transcriptional activities of Heat Shock factor-1
###end article-title 68
###begin article-title 69
Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells
###end article-title 69
###begin article-title 70
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
###end article-title 70
###begin article-title 71
The p53 tumor suppresser protein is phosphorylated at serine 389 by casein kinase II
###end article-title 71
###begin article-title 72
Phosphorylation of the tumor suppressor p53 by mitogen activated kinases
###end article-title 72
###begin article-title 73
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 116 121 <span type="species:ncbi:9606">human</span>
Human DNA activated protein kinase phosphorylates serines 15 and 37 in the amino terminal transactivation domain of human p53
###end article-title 73
###begin article-title 74
Regulation of the p53 protein by protein kinase Calpha and protein kinase Cepsilon
###end article-title 74
###begin article-title 75
Conformation-dependent phosphorylation of p53
###end article-title 75
###begin article-title 76
JNK targets p53 ubiquitination and degradation in nonstressed cells
###end article-title 76
###begin article-title 77
Molecular cloning and expression of glycogen synthase kinase-3/Factor A
###end article-title 77
###begin article-title 78
Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappa B activation
###end article-title 78
###begin article-title 79
###xml 34 39 <span type="species:ncbi:9606">human</span>
Mutations in serines 15 and 20 of human p53 impair its apoptotic activity
###end article-title 79
###begin article-title 80
Regulation of p53 function and stability by phosphorylation
###end article-title 80
###begin article-title 81
DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation
###end article-title 81
###begin article-title 82
DNA-dependent protein kinase gets a break: its role in repairing DNA and maintaining genomic integrity
###end article-title 82
###begin article-title 83
DNA-dependent protein kinase acts upstream of p53 in response to DNA damage
###end article-title 83
###begin article-title 84
DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage
###end article-title 84
###begin article-title 85
A role for ATR in the DNA damage-induced phosphorylation of p53
###end article-title 85
###begin article-title 86
p53 is phosporylated by CDK7-cyclin H in a p36mat1 dependent manner
###end article-title 86
###begin article-title 87
A role for p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents
###end article-title 87
###begin article-title 88
Cellular survival: a play in three akts
###end article-title 88
###begin article-title 89
Ras regulates sympathetic neuron survival by suppressing the p53-mediated cell death pathway
###end article-title 89
###begin article-title 90
Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis
###end article-title 90
###begin article-title 91
Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53
###end article-title 91

